Feb 7 (Reuters) - Revive Therapeutics Ltd RVV.V
* Revive Therapeutics announces initiation of a Phase 2 study of revenue-004 (bucillamine) in cystinuria Source text for Eikon: ID:nCCN85Llhl Further company coverage: RVV.V
Feb 7 (Reuters) - Revive Therapeutics Ltd RVV.V
* Revive Therapeutics announces initiation of a Phase 2 study of revenue-004 (bucillamine) in cystinuria Source text for Eikon: ID:nCCN85Llhl Further company coverage: RVV.V